<DOC>
	<DOC>NCT00238992</DOC>
	<brief_summary>All patients of the core study who are interested of being treated with EC-MPS will be included in an open-label extension study to collect further information on the long-term safety, tolerability and efficacy of this drug. The purpose of this study is to evaluate the feasibility of steroid withdrawal in the setting of immunosuppression with a combination of EC-MPS, cyclosporine and steroids in de novo kidney allograft recipients.</brief_summary>
	<brief_title>Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion Criteria Male or female patients undergoing first kidney transplant. Patients aged 18 70 years. Patients receiving an ABO identical or compatible graft. Exclusion Criteria Multiorgan recipients (e.g. kidney and pancreas) or previous transplant with any organ other than kidney. Positive HBsAg test PreTransplant PRA &gt;50% or historical PRA &gt;75% Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Kidney, de novo transplant, steroid withdrawal, adults, EC-MPS and cyclosporine</keyword>
</DOC>